CT纹理分析作为酪氨酸激酶抑制剂治疗转移性肺腺癌的预测因素
研究对50例接受酪氨酸激酶抑制剂治疗的转移性肺腺癌患者治疗前增强CT进行纹理分析,基于5个纹理参数的无创特征预测6个月进展AUC为0.8、1年进展AUC为0.76,高危组进展风险比分别为4.63和5.78,纹理特征与总生存无相关性。
要点
- 治疗前CT纹理特征可能预测TKI治疗转移性肺腺癌的6个月和1年进展。
- 基于5个纹理参数的特征预测6个月进展AUC为0.8、1年进展AUC为0.76。
- 按中位数和最佳截断值分组,高危组进展风险比分别为4.63和5.78。
核心结论
- 纹理特征似乎与TKI治疗的肺腺癌无进展生存相关,但与总生存无相关性。
研究设计与样本
- 研究对50例接受TKI治疗的转移性肺腺癌患者治疗前增强CT进行纹理分析,使用商用软件(TexRAD Ltd,Cambridge,UK),在原发性肿瘤5 mm厚中心层面量化纹理特征,采用内部交叉验证的机器学习方法并与无进展生存和总生存进行相关性分析,随后在自助法样本中验证。
诊断标准与关键数值
- 基于5个纹理参数的无创特征预测6个月进展的AUC为0.8(95% CI)。
- 基于5个纹理参数的无创特征预测1年进展的AUC为0.76。
- 按中位数分组高危组进展风险比为4.63,按最佳截断值分组高危组进展风险比为5.78。
- 纹理特征与总生存无相关性。
- 可用临床变量与无进展生存或总生存均无相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the predictive and prognostic value of pre-treatment CT texture features in lung adenocarcinoma treated with tyrosine kinase inhibitors (TKI).
MATERIALS AND METHODS: Texture analysis was performed using commercially available software (TexRAD Ltd, Cambridge, UK) on pre-treatment contrast-enhanced CT studies from 50 patients with metastatic lung adenocarcinoma treated by TKI. Texture features were quantified on a 5-mm-thick central slice of the primary tumor and were correlated with progression-free and overall survival (PFS and OS) using an internally cross-validated machine learning approach then validated on a bootstrapped sample.
RESULTS: Median PFS and OS were 10.5 and 20.7 months, respectively. A noninvasive signature based on five texture parameters predicted 6-month progression with Area Under the Curve (AUC) of 0.8 (95% CI) and 1-year progression with AUC of 0.76. A high-risk group had hazard ratios for progression of 4.63 and 5.78 when divided by median and best cut-off points, respectively. Texture signature did not correlate with OS. Available clinical variables did not correlate with PFS or with OS.
CONCLUSION: Texture features seem to be associated with PFS in lung adenocarcinoma treated with TKI.
引用
- Ravanelli M, Agazzi GM, Ganeshan B, et al. CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). Eur J Radiol. 2018. PMID: 30527295. doi:10.1016/j.ejrad.2018.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。